Gene Therapy Targeting Receptor-Mediated Cell Death to Cancers

  • Lidong Zhang
  • Bingliang Fang
Chapter
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

Research has demonstrated that delivery of genes encoding tumor necrosis factor (TNF)-α, Fas ligand (FasL), and TNF-related apoptosis-inducing ligand (TRAIL) to tumors can elicit apoptosis in cancer cells and can induce local inflammatory response, leading to regression of cancers. Constitutively active death receptors or chimeric death receptors that can be activated by other ligands, such as vascular endothelial growth factor, have also been exploited for cancer gene therapy. Systemic toxicity of death ligands can be prevented by using genes encoding membrane-bound death ligands and by targeted transgene expression through either targeted transduction or targeted transcription. Improvements have been made for tumor-selective transgene expressions. Various studies have demonstrated that the human telomerase reverse transcriptase promoter, whose gene is active in over 85% of cancers but not in normal cells, can drive tumor-specific transgene expression in a variety of cancer types. Moreover, transgene expression from a tumor-specific promoter can be augmented via transcriptional factors without loss of specificity. Thus far, reported data have shown that targeted expression of TRAIL, FasL, and TNF-α effectively suppressed tumor growth with minimal systemic toxicity. Challenges remain for treatment of metastatic diseases and for overcoming resistances. Here we summarize recent advances in targeted cancer gene therapy with receptor-mediated death pathways.

Keywords

Toxicity Leukemia Adenocarcinoma Oncol Sarcoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. 1.
    Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trend Biochem Sci 2002;27:19–26.PubMedCrossRefGoogle Scholar
  2. 2.
    Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487–501.PubMedCrossRefGoogle Scholar
  3. 3.
    Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002;296:1634–1635.PubMedCrossRefGoogle Scholar
  4. 4.
    Brown TD, Goodman P, Fleming T, Macdonald JS, Hersh EM, Braun TJ. A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas: a Southwest Oncology Group study. J Immunother 1991;10:376–378.PubMedCrossRefGoogle Scholar
  5. 5.
    Kemeny N, Childs B, Larchian W, Rosado K, Kelsen D. A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. Cancer 1990;66:659–663.PubMedCrossRefGoogle Scholar
  6. 6.
    Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806–809.PubMedCrossRefGoogle Scholar
  7. 7.
    Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000;6:564–567.PubMedCrossRefGoogle Scholar
  8. 8.
    Nitsch R, Bechmann I, Deisz RA, et al. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 2000;356:827–828.PubMedCrossRefGoogle Scholar
  9. 9.
    Zamai L, Secchiero P, Pierpaoli S, et al. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood 2000;95:3716–3724.PubMedGoogle Scholar
  10. 10.
    Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001;7:383–385.PubMedCrossRefGoogle Scholar
  11. 11.
    Roth JA, Grammer SF, Swisher SG, et al. Gene therapy approaches for the management of non-small cell lung cancer. Seminar Oncol 2001;28:50–56.CrossRefGoogle Scholar
  12. 12.
    Smith AE. Viral vectors in gene therapy. Ann Rev Microbiol 1995;49:807–838.CrossRefGoogle Scholar
  13. 13.
    Kovesdi I, Brough DE, Bruder JT, Wickham TJ. Adenoviral vectors for gene transfer. Cur Opinion Biotech 1997;8:583–589.CrossRefGoogle Scholar
  14. 14.
    Wickham TJ. Targeting adenovirus. Gene Ther 2000;7:110–114.PubMedCrossRefGoogle Scholar
  15. 15.
    Barnett BG, Crews CJ, Douglas JT. Targeted adenoviral vectors. Biochim Biophys Acta 2002;1575:1–14.PubMedGoogle Scholar
  16. 16.
    Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotech 1996;14:1574–1578.CrossRefGoogle Scholar
  17. 17.
    Gu DL, Gonzalez AM, Printz MA, et al. Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. Cancer Res 1999;59:2608–2614.PubMedGoogle Scholar
  18. 18.
    Goldman CK, Rogers BE, Douglas JT, et al. Targeted gene delivery to Kaposi’s sarcoma cells via the fibroblast growth factor receptor. Cancer Res 1997;57:1447–1451.PubMedGoogle Scholar
  19. 19.
    Van Beusechem VW, Grill J, Mastenbroek DC, et al. Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. J Virol 2002;76:2753–2762.PubMedCrossRefGoogle Scholar
  20. 20.
    Miller CR, Buchsbaum DJ, Reynolds PN, et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998;58:5738–5748.PubMedGoogle Scholar
  21. 21.
    Nettelbeck DM, Miller DW, Jerome V, et al. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol Ther 2001; 3:882–891.PubMedCrossRefGoogle Scholar
  22. 22.
    Wesseling JG, Bosma PJ, Krasnykh V, et al. Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther 2001;8:969–976.PubMedCrossRefGoogle Scholar
  23. 23.
    Dmitriev I, Kashentseva E, Rogers BE, Krasnykh V, Curiel DT. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol 2000;74:6875–6884.PubMedCrossRefGoogle Scholar
  24. 24.
    Stevenson SC, Rollence M, Marshall-Neff J, McClelland A. Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J Virol 1997;71:4782–4790.PubMedGoogle Scholar
  25. 25.
    Yotnda P, Onishi H, Heslop HE, et al. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther 2001;8:930–937.PubMedCrossRefGoogle Scholar
  26. 26.
    Wickham TJ, Roelvink PW, Brough DE, Kovesdi I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotech 1996;14:1570–1573.CrossRefGoogle Scholar
  27. 27.
    Pearson AS, Koch PE, Atkinson N, et al. Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. Clin Cancer Res 1999;5:4208–4213.PubMedGoogle Scholar
  28. 28.
    Wickham TJ, Tzeng E, Shears LL 2nd, et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997;71:8221–8229.PubMedGoogle Scholar
  29. 29.
    Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998;72:9706–9713.PubMedGoogle Scholar
  30. 30.
    Lamfers ML, Grill J, Dirven CM, et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 2002;62:5736–5742.PubMedGoogle Scholar
  31. 31.
    Asada-Mikami R, Heike Y, Kanai S, et al. Efficient gene transduction by RGD-fiber modified recombinant adenovirus into dendritic cells. Japan J Cancer Res 2001;92:321–327.Google Scholar
  32. 32.
    Kasahara N, Dozy AM, Kan YW. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 1994;266:1373–1376.PubMedCrossRefGoogle Scholar
  33. 33.
    Gollan TJ, Green MR. Selective targeting and inducible destruction of human cancer cells by retroviruses with envelope proteins bearing short peptide ligands. J Virol 2002;76:3564–3569.PubMedCrossRefGoogle Scholar
  34. 34.
    Martin F, Chowdhury S, Neil S, Phillipps N, Collins MK. Envelope-targeted retrovirus vectors transduce melanoma xenografts but not spleen or liver. Mol Ther 2002;5:269–274.PubMedCrossRefGoogle Scholar
  35. 35.
    Cosset FL, Morling FJ, Takeuchi Y, Weiss RA, Collins MK, Russell SJ. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol 1995;69:6314–6322.PubMedGoogle Scholar
  36. 36.
    Wolschek MF, Thallinger C, Kursa M, et al. Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice. Hepatol 2002;36:1106–1114.CrossRefGoogle Scholar
  37. 37.
    Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377–380.PubMedCrossRefGoogle Scholar
  38. 38.
    Koivunen E, Arap W, Valtanen H, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotech 1999;17:768–774.CrossRefGoogle Scholar
  39. 39.
    Nicklin SA, White SJ, Watkins SJ, Hawkins RE, Baker AH. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation 2000;102:231–237.PubMedGoogle Scholar
  40. 40.
    Kolonin M, Pasqualini R, Arap W. Molecular addresses in blood vessels as targets for therapy. Curr Opinion Chem Biol 2001;5:308–313.CrossRefGoogle Scholar
  41. 41.
    Pasqualini R, Koivunen E, Ruoslahti E. A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins. J Cell Biol 1995;130:1189–1196.PubMedCrossRefGoogle Scholar
  42. 42.
    Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000;60:722–727.PubMedGoogle Scholar
  43. 43.
    Liu L, Anderson WF, Beart RW, Gordon EM, Hall FL. Incorporation of tumor vasculature targeting motifs into moloney murine leukemia virus env escort proteins enhances retrovirus binding and transduction of human endothelial cells. J Virol 2000;74:5320–5328.PubMedCrossRefGoogle Scholar
  44. 44.
    Roelvink PW, Mi LG, Einfeld DA, Kovesdi I, Wickham TJ. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 1999;286:1568–1571.PubMedCrossRefGoogle Scholar
  45. 45.
    Pizzato M, Blair ED, Fling M, et al. Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells. Gene Ther 2001;8:1088–1096.PubMedCrossRefGoogle Scholar
  46. 46.
    Leissner P, Legrand V, Schlesinger Y, et al. Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism. Gene Ther 2001;8:49–57.PubMedCrossRefGoogle Scholar
  47. 47.
    Nettelbeck DM, Jerome V, Muller R. Gene therapy: designer promoters for tumour targeting. Trend Genet 2000;16:174–181.CrossRefGoogle Scholar
  48. 48.
    Clary BM, Lyerly HK. Transcriptional targeting for cancer gene therapy. Surg Oncol Clinic North Am 1998;7:565–574.Google Scholar
  49. 49.
    Osaki T, Tanio Y, Tachibana I, et al. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 1994;54:5258–5261.PubMedGoogle Scholar
  50. 50.
    Richards CA, Austin EA, Huber BE. Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 1995;6:881–893.PubMedGoogle Scholar
  51. 51.
    Ido A, Nakata K, Kato Y, et al. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res 1995;55:3105–3109.PubMedGoogle Scholar
  52. 52.
    Kaneko S, Hallenbeck P, Kotani T, et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 1995;55:5283–5287.PubMedGoogle Scholar
  53. 53.
    Andriani F, Nan B, Yu J, et al. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. J Natl Cancer Inst 2001;93:1314–1324.PubMedCrossRefGoogle Scholar
  54. 54.
    Gotoh A, Ko SC, Shirakawa T, et al. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J Urol 1998;160:220–229.PubMedCrossRefGoogle Scholar
  55. 55.
    Chen L, Chen D, Manome Y, Dong Y, Fine HA, Kufe DW. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest 1995;96:2775–2782.PubMedGoogle Scholar
  56. 56.
    Parr MJ, Manome Y, Tanaka T, et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med 1997;3:1145–1149.PubMedCrossRefGoogle Scholar
  57. 57.
    Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 1989;59:521–529.PubMedCrossRefGoogle Scholar
  58. 58.
    Blackburn EH. Telomerases. Ann Rev Biochem 1992;61:113–129.PubMedCrossRefGoogle Scholar
  59. 59.
    Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458–460.PubMedCrossRefGoogle Scholar
  60. 60.
    Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011–2015.PubMedCrossRefGoogle Scholar
  61. 61.
    Counter CM, Avilion AA, LeFeuvre CE, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992;11:1921–1929.PubMedGoogle Scholar
  62. 62.
    Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. European Journal of Cancer 1997;33:787–791.PubMedCrossRefGoogle Scholar
  63. 63.
    Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277:955–959.PubMedCrossRefGoogle Scholar
  64. 64.
    Holt SE, Aisner DL, Shay JW, Wright WE. Lack of cell cycle regulation of telomerase activity in human cells. Proc Natl Acad Sci USA 1997;94:10,687–10,692.PubMedCrossRefGoogle Scholar
  65. 65.
    Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998;279:349–352.PubMedCrossRefGoogle Scholar
  66. 66.
    Toouli CD, Huschtscha LI, Neumann AA, et al. Comparison of human mammary epithelial cells immortalized by simian virus 40 T-antigen or by the telomerase catalytic subunit. Oncogene 2002;21:128–139.PubMedCrossRefGoogle Scholar
  67. 67.
    Elenbaas B, Spirio L, Koerner F, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Gene Develop 2001;15:50–65.CrossRefGoogle Scholar
  68. 68.
    Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464–468.PubMedCrossRefGoogle Scholar
  69. 69.
    Takakura M, Kyo S, Kanaya T, et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequence essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999;59:551–557.PubMedGoogle Scholar
  70. 70.
    Horikawa I, Cable PL, Afshari C, Barrett JC. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 1999;59:826–830.PubMedGoogle Scholar
  71. 71.
    Wu KJ, Grandori C, Amacker M, et al. Direct activation of TERT transcription by c-MYC. Nat Genet 1999;21:220–224.PubMedCrossRefGoogle Scholar
  72. 72.
    Abdul-Ghani R, Ohana P, Matouk I, et al. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol Ther 2000;2:539–544.PubMedCrossRefGoogle Scholar
  73. 73.
    Gu J, Kagawa S, Takakura M, et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 2000;60:5359–5364.PubMedGoogle Scholar
  74. 74.
    Komata T, Kondo Y, Kanzawa T, et al. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res 2001;61:5796–5802.PubMedGoogle Scholar
  75. 75.
    Gu J, Andreeff M, Roth JA, Fang B. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther 2002;9:30–37.PubMedCrossRefGoogle Scholar
  76. 76.
    Gu J, Zhang L, Huang X, et al. A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo. Oncogene 2002;21:4757–4764.PubMedCrossRefGoogle Scholar
  77. 77.
    Huang X, Lin T, Gu J, et al. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft. Gene Ther 2002;9:1379–1386.PubMedCrossRefGoogle Scholar
  78. 78.
    Lin T, Gu J, Zhang L, et al. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effect on primary human hepatocytes. Cancer Res 2002;62:3620–3625.PubMedGoogle Scholar
  79. 79.
    Lin T, Huang X, Gu J, et al. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 2002;21:8020–8028.PubMedCrossRefGoogle Scholar
  80. 80.
    Koga S, Hirohata S, Kondo Y, et al. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther 2000;11:1397–1406.PubMedCrossRefGoogle Scholar
  81. 81.
    Koga S, Hirohata S, Kondo Y, et al. FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo. Anticancer Res 2001;21:1937–1943.PubMedGoogle Scholar
  82. 82.
    Nagayama Y, Nishihara E, Iitaka M, Namba H, Yamashita S, Niwa M. Enhanced efficacy of transcriptionally targeted suicide gene/prodrug therapy for thyroid carcinoma with the Cre-loxP system. Cancer Res 1999;59:3049–3052.PubMedGoogle Scholar
  83. 83.
    Ueda K, Iwahashi M, Nakamori M, Nakamura M, Yamaue H, Tanimura H. Enhanced selective gene expression by adenovirus vector using Cre/loxP regulation system for human carcinoembryonic antigen-producing carcinoma. Oncology 2000;59:255–265.PubMedCrossRefGoogle Scholar
  84. 84.
    Nettelbeck DM, Jerome V, Muller R. A strategy for enhancing the transcriptional activity of weak cell type-specific promoters. Gene Ther 1998;5:1656–1664.PubMedCrossRefGoogle Scholar
  85. 85.
    Borovjagin AV, Ezrokhi MV, Rostapshov VM, Ugarova TY, Bystrova TF, Shatsky IN. RNA-protein interactions within the internal translation initiation region of encephalomyocarditis virus RNA. Nucleic Acid Res 1991;19:4999–5005.PubMedCrossRefGoogle Scholar
  86. 86.
    Sadowski I, Ma J, Triezenberg S, Ptashne M. GAL4-VP16 is an unusually potent transcriptional activator. Nature 1988;335:563–564.PubMedCrossRefGoogle Scholar
  87. 87.
    Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992;89:5547–5551.PubMedCrossRefGoogle Scholar
  88. 88.
    Koch P, Guo ZS, Kagawa S, Gu J, Roth JA, Fang B. Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. Mol Ther 2001;3:278–283.PubMedCrossRefGoogle Scholar
  89. 89.
    Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673–682.PubMedCrossRefGoogle Scholar
  90. 90.
    Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12,687–12,690.PubMedCrossRefGoogle Scholar
  91. 91.
    Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157–163.PubMedCrossRefGoogle Scholar
  92. 92.
    Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155–162.PubMedCrossRefGoogle Scholar
  93. 93.
    Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000;165:2886–2894.PubMedGoogle Scholar
  94. 94.
    Kagawa S, He C, Gu J, et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001;61:3330–3338.PubMedGoogle Scholar
  95. 95.
    Mariani SM, Matiba B, Armandola EA, Krammer PH. Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J Cell Biol 1997;137:221–229.PubMedCrossRefGoogle Scholar
  96. 96.
    Mariani SM, Krammer PH. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol 1998;28:973–982.PubMedCrossRefGoogle Scholar
  97. 97.
    Gores GJ, Kaufmann SH. Is TRAIL hepatotoxic? Hepatol 2001;34:3–6.CrossRefGoogle Scholar
  98. 98.
    Kagawa S, Gu J, Honda T, et al. Deficiency of caspase-3 in MCF7 cells blocks Bax-mediated nuclear fragmentation but not cell death. Clin Cancer Res 2001;7:1474–1480.PubMedGoogle Scholar
  99. 99.
    Voelkel-Johnson C, King DL, Norris JS. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther 2002;9:164–172.PubMedCrossRefGoogle Scholar
  100. 100.
    Seino K, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nat Med 1997;3:165–170.PubMedCrossRefGoogle Scholar
  101. 101.
    Aoki K, Akyurek LM, San H, et al. Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy. Mol Ther 2000;1:555–565.PubMedCrossRefGoogle Scholar
  102. 102.
    Arai H, Gordon D, Nabel EG, Nabel GJ. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA 1997;94:13,862–13,867.PubMedCrossRefGoogle Scholar
  103. 103.
    Hyer ML, Voelkel-Johnson C, Rubinchik S, Dong J, Norris JS. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol Ther 2000;2:348–358.PubMedCrossRefGoogle Scholar
  104. 104.
    Rubinchik S, Ding R, Qiu AJ, Zhang F, Dong J. Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system. Gene Ther 2000;7:875–885.PubMedCrossRefGoogle Scholar
  105. 105.
    Chung TD, Mauceri HJ, Hallahan DE, et al. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther 1998;5:344–349.PubMedGoogle Scholar
  106. 106.
    Jerome V, Muller R. Tissue-specific, cell cycle-regulated chimeric transcription factors for the targeting of gene expression to tumor cells. Hum Gene Ther 1998;9:2653–2659.PubMedGoogle Scholar
  107. 107.
    Mizuguchi H, Nakagawa T, Toyosawa S, et al. Tumor necrosis factor alpha-mediated tumor regression by the in vivo transfer of genes into the artery that leads to tumors. Cancer Res 1998;58:5725–5730.PubMedGoogle Scholar
  108. 108.
    Staba MJ, Mauceri HJ, Kufe DW, Hallahan DE, Weichselbaum RR. Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther 1998;5:293–300.PubMedCrossRefGoogle Scholar
  109. 109.
    Walther W, Wendt J, Stein U. Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy. Gene Ther 1997;4:544–552.PubMedCrossRefGoogle Scholar
  110. 110.
    Wright P, Braun R, Babiuk L, et al. Adenovirus-mediated TNF-alpha gene transfer induces significant tumor regression in mice. Cancer Biother Radiopharm 1999;14:49–57.PubMedCrossRefGoogle Scholar
  111. 111.
    Gautam SC, Xu YX, Pindolia KR, Yegappan R, Janakiraman N, Chapman RA. TNF-alpha gene therapy with myeloid progenitor cells lacks the toxicities of systemic TNF-alpha therapy. J Hematother 1999;8:237–245.PubMedCrossRefGoogle Scholar
  112. 112.
    Hofmann A, Blau HM. Death of solid tumor cells induced by Fas ligand expressing primary myoblasts. Som Cell Mol Genet 1997;23:249–257.CrossRefGoogle Scholar
  113. 113.
    Gearing AJ, Beckett P, Christodoulou M, et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994;370:555–557.PubMedCrossRefGoogle Scholar
  114. 114.
    Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729–733.PubMedCrossRefGoogle Scholar
  115. 115.
    Powell WC, Fingleton B, Wilson CL, Boothby M, Matrisian LM. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 1999;9:1441–1447.PubMedCrossRefGoogle Scholar
  116. 116.
    Hersh EM, Metch BS, Muggia FM, et al. Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience. J Immunother 1991;10:426–431.PubMedCrossRefGoogle Scholar
  117. 117.
    Schneider P, Holler N, Bodmer JL, et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998;187:1205–1213.PubMedCrossRefGoogle Scholar
  118. 118.
    Tanaka M, Suda T, Yatomi T, Nakamura N, Nagata S. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J Immunol 1997;158:2303–2309.PubMedGoogle Scholar
  119. 119.
    Marr RA, Addison CL, Snider D, Muller WJ, Gauldie J, Graham FL. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha. Gene Ther 1997;4:1181–1188.PubMedCrossRefGoogle Scholar
  120. 120.
    Rubinchik S, Wang D, Yu H, et al. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression. Mol Ther 2001;4:416–426.PubMedCrossRefGoogle Scholar
  121. 121.
    Mauceri HJ, Hanna NN, Wayne JD, Hallahan DE, Hellman S, Weichselbaum RR. Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res 1996;56:4311–4314.PubMedGoogle Scholar
  122. 122.
    Modlich U, Pugh CW, Bicknell R. Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Ther 2000;7:896–902.PubMedCrossRefGoogle Scholar
  123. 123.
    Datta R, Rubin E, Sukhatme V, et al. Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc Natl Acad Sci USA 1992;89:10,149–10,153.PubMedCrossRefGoogle Scholar
  124. 124.
    Bazzoni F, Alejos E, Beutler B. Chimeric tumor necrosis factor receptors with constitutive signaling activity. Proc Natl Acad Sci USA 1995;92:5376–5380.PubMedCrossRefGoogle Scholar
  125. 125.
    Bazzoni F, Regalia E. Triggering of antitumor activity through melanoma-specific transduction of a constitutively active tumor necrosis factor (TNF) R1 chimeric receptor in the absence of TNF-alpha. Cancer Res 2001;61:1050–1057.PubMedGoogle Scholar
  126. 126.
    Quinn TP, Soifer SJ, Ramer K, Williams LT, Nakamura MC. A receptor for vascular endothelial growth factor that stimulates endothelial apoptosis. Cancer Res 2001;61:8629–8637.PubMedGoogle Scholar
  127. 127.
    Carpenito C, Davis PD, Dougherty ST, Dougherty GJ. Exploiting the differential production of angiogenic factors within the tumor microenvironment in the design of a novel vascular-targeted gene therapy-based approach to the treatment of cancer. Int J Rad Oncol Biol Phys 2002;54:1473–1478.CrossRefGoogle Scholar
  128. 128.
    Zhang L, Gu J, Lin T, Huang X, Roth JA, Fang B. Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line. Gene Ther 2002;9:1262–1270.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Authors and Affiliations

  • Lidong Zhang
    • 1
  • Bingliang Fang
    • 1
  1. 1.Department of Thoracic and Cardiovascular SurgeryThe University of Texas MD Anderson Cancer CenterHouston

Personalised recommendations